Fluorofenidone attenuates oxidative stress and renal fibrosis in obstructive nephropathy via blocking nox2 (gp91phox) expression and inhibiting erk/mapk signaling pathway

Kidney and Blood Pressure Research

Volumn 40, Issue 1, 2015, Pages 89-99

  Qin, Jiao ^a   Mei, Wen Juan ^b   Xie, Yan Yun ^b   Huang, Ling ^b   Yuan, Qiong Jing ^b   Hu, Gao Yun ^c   Tao, Li Jian ^b   Peng, Zhang Zhe ^b  

^a CHANGSHA CENTRAL HOSPITAL   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c Faculty of Pharmaceutical Sciences   (China)

Author keywords

ERK; Fluorofenidone; Losartan; NOX2 (gp91phox); Obstructive nephropathy

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; ANGIOTENSIN II; COLLAGEN TYPE 1; FIBRONECTIN; FLUOROFENIDONE; LOSARTAN; MALONALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE; PYRIDONE DERIVATIVE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; UNCLASSIFIED DRUG; 5-METHYL-1-(3-FLUOROPHENYL)-2-(1H)-PYRIDONE; CYBB PROTEIN, RAT; MEMBRANE PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; COLLAGEN FIBER; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME PHOSPHORYLATION; KIDNEY CORTEX; KIDNEY DISEASE; KIDNEY EPITHELIUM; KIDNEY FIBROSIS; LIPID PEROXIDATION; MALE; NONHUMAN; OBSTRUCTIVE NEPHROPATHY; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RENAL PROTECTION; SIGNAL TRANSDUCTION; THERAPY EFFECT; URETER OBSTRUCTION; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; DRUG EFFECTS; ENZYMOLOGY; FIBROSIS; GENE EXPRESSION REGULATION; KIDNEY DISEASES; PATHOLOGY; PHYSIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; FIBROSIS; GENE EXPRESSION REGULATION, ENZYMOLOGIC; KIDNEY DISEASES; MALE; MAP KINASE SIGNALING SYSTEM; MEMBRANE GLYCOPROTEINS; NADPH OXIDASE; OXIDATIVE STRESS; PYRIDONES; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84925367885     PISSN: 14204096     EISSN: 14230143     Source Type: Journal    
DOI: 10.1159/000368485     Document Type: Article

References (27)

1. Klahr S, Morrissey J: Obstructive nephropathy and renal fibrosis. Am J Physiol Renal Physiol 2002;283:F861-F875
2. Qin J, Xie YY, Huang L, Yuan QJ, Mei WJ, Yuan XN, Hu GY, Cheng GJ, Tao LJ, Peng ZZ: Fluorofenidone inhibits nicotinamiDe aDeninedinucleotiDe phosphate oxidase via PI3K/Akt pathway in the pathogenesis of renal interstitial fibrosis. Nephrology (Carlton) 2013;18:690-699
3. Dendooven A, Ishola Jr. DA, Nguyen TQ, Van Der Giezen DM, Kok RJ, Goldschmeding R, Joles JA: Oxidative stress in obstructive nephropathy. Int J Exp Path 2011;92:202-210
4. Touyz RM, Briones AM, SeDeek M, Burger D, Montezano AC: NOX Isoforms and Reactive Oxygen Species in Vascular Health. Mol Interv 2011;11:27-35
5. Wolak T, Kim HJ, Ren Y, Kim J, Vaziri ND, Nicholas SB: Osteopontin modulates angiotensin II-induced inflammation, oxidative stress, and fibrosis of the kidney. Kidney Int 2009;76:32-43
6. Garrido AM, Griendling KK: NADPH oxidases and angiotensin II receptor signaling. Mol Cell Endocrinol 2009;302:148-158
7. Sachse A, Wolf G: Angiotensin II-Induced Reactive Oxygen Species and the Kidney. J Am Soc Nephrol 2007;18:2439-2446
8. Meng JZ, Hu C, Zhu Y, Peng Z, Hu G, Wang Z, Tao L: Fluorofenidone attenuates bleomycin-induced pulmonary inflammation and fibrosis in mice via restoring caveolin 1 expression and inhibiting mitogenactivated protein kinase signaling pathway. Shock 2012;38:567-573
9. Peng ZZ, Hu GY, Shen H, Wang L, Ning WB, Xie YY, Wang NS, Li BX, Tang YT, Tao LJ: Fluorofenidone attenuates collagen I and transforming growth factor-beta1 expression through a nicotinamiDe aDenine dinucleotiDe phosphate oxidase-DepenDent way in NRK-52E cells. Nephrology (Carlton) 2009;14:565-572
10. Chen LX, Yang K, Sun M, Chen Q, Wang ZH, Hu GY, Tao LJ: Fluorofenidone inhibits transforming growth factor-beta1-induced cardiac myofibroblast differentiation. Pharmazie 2012;67:452-456
11. Peng Y, Yang H, Zhu T, Zhao M, Deng Y: The antihepatic fibrotic effects of fluorofenidone via MAPK signalling pathways. Eur J Clin Invest 2013;43:358-368
12. Forbes JM, Coughlan MT, Cooper ME: Oxidative Stress as a Major Culprit in Kidney Disease in Diabetes. Diabetes 2008;57:1446-1454
13. Moriyama T, Kawada N, Nagatoya K, Takeji M, Horio M, Ando A, Imai E, Hori M: Fluvastatin suppresses oxidative stress and fibrosis in the interstitium of mouse kidneys with unilateral ureteral obstruction. Kidney Int 2001;59:2095-2103
14. Ozbek E, Ilbey YO, Ozbek M, Simsek A, Cekmen M, Somay A: Melatonin Attenuates Unilateral Ureteral Obstruction-Induced Renal Injury by Reducing Oxidative Stress, iNOS, MAPK, and NF-kB Expression. J Endourol 2009;23:1165-1173
15. Kimura S, Zhang GX, Nishiyama A, Shokoji T, Yao L, Fan YY, Rahman M, Suzuki T, Maeta H, Abe Y: Role of NAD(P)H oxidase-And mitochondria-Derived reactive oxygen species in cardioprotection of ischemic reperfusion injury by angiotensin II. Hypertension 2005;45:860-866
16. Singh U, Jialal I: Oxidative stress and atherosclerosis. Pathophysiology 2006;13:129-142
17. Geiszt M, Kopp JB, Vrnai P, Leto TL: IDentification of Renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci USA 2000;97:8010-8014
18. Folli F, Corradi D, Fanti P, Davalli A, Paez A, Giaccari A, Perego C, Muscogiuri G: The Role of Oxidative Stress in the Pathogenesis of Type 2 Diabetes Mellitus Micro-And Macrovascular Complications: Avenues for a Mechanistic-Based Therapeutic Approach. Curr Diabetes Rev 2011;7:313-324
19. Bondi CD, Manickam N, Lee DY, Block K, Gorin Y, Abboud HE, Barnes JL: NAD(P)H Oxidase Mediates TGF-β1-Induced Activation of Kidney Myofibroblasts. J Am Soc Nephrol 2010;21:93-102
20. Zhang GX, Lu XM, Kimura S, Nishiyama A: Role of mitochondria in angiotensin II-induced reactive oxygen species and mitogen-Activated protein kinase activation. Cardiovasc Res 2007;76:204-212
21. Rhyu DY, Park J, Sharma BR, Ha H: Role of reactive oxygen species in transforming growth factor-beta1-induced extracellular matrix accumulation in renal tubular epithelial cells. Transplant Proc 2012;44:625-628
22. Okada H, Kalluri R: Cellular and Molecular Pathways that Lead to Progression and Regression of Renal Fibrogenesis. Curr Mol Med 2005;5:467-474
23. Yuan Q, Wang R, Peng Y, Fu X, Wang W, Wang L, Zhang F, Peng Z, Ning W, Hu G, Wang Z, Tao L: Fluorofenidone attenuates tubulointerstitial fibrosis by inhibiting TGF-β(1)-induced fibroblast activation. Am J Nephrol 2011;34:181-194
24. Wang L, Hu GY, Shen H, Peng ZZ, Ning WB, Tao LJ: Fluorofenidone inhibits TGF-beta1 induced CTGF via MAPK pathways in mouse mesangial cells. Pharmazie 2009;64:680-684
25. Brenner BM, Cooper ME: Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. N Engl J Med 2001;345:861-869
26. Chabrashvili T, Kitiyakara C, Blau J, Karber A, Aslam S, Welch WJ, Wilcox CS: Effects of ANG II type 1 and 2 receptors on oxidative stress, renal NADPH oxidase, and SOD expression. Am J Physiol Regul Integr Comp Physiol 2003;285:R117-R124
27. Xiong X, Mei W, Xie Y, Liu J, Lu M, Peng X, Yang C, Zhang X, Xie M, Luo R, Yuan X, Huang L, Wu L, Qin J, Peng Y, Jia X, Hu G, Tang D, Tao L: Fluorofenidone Offers Improved Renoprotection at Early Interventions during the Course of Diabetic Nephropathy in db-db Mice via Multiple Pathways. PLos One 2014;27:e111242